STOCKHOLM, September 4 /PRNewswire/ -- Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development's business strategy.
Dilafor's candidate drug, tafoxiparin DF01 is one of 11 compounds within the Karolinska Development portfolio that are currently conducting clinical trials. The completion of the Dilafor study is an important milestone for Karolinska Development and exemplifies the company's ability to develop innovative ideas through to clinical proof of concept quickly and efficiently. In the case of Dilafor, tafoxiparin has taken just six years to go from research concept to its current stage.
Karolinska Development's portfolio consists of more than 40 life science companies. A unique business model, which gives portfolio companies access to a broad network of business, legal, regulatory and scientific expertise, means that development times and costs are reduced compared to traditional drug development programs. With seven compounds currently undergoing Phase II clinical trials and five in Phase I the portfolio has matured to the point that Karolinska Development is now actively seeking commercial partners for its most advanced projects.
Conny Bogentoft, CEO of Karolinska Development, said, "The completion of
the Dilafor Phase II trial is an important step for Karolinska Development
and we are extremely pleased that Dilafor has achieved some very positive
results. At the same time, it also goes a long way towards validating our
business model. We are now very much focused on finding commercial
opportunities for Dilafor's tafoxiparin and for several of our other projects
that are reachin
|SOURCE Karolinska Development AB PUBL|
Copyright©2009 PR Newswire.
All rights reserved